FDA New Approval — Mar 19, 2024

Tryvio™ (aprocitentan)

Overview

Manufacturer	Idorsia Pharmaceuticals U.S. Inc.
Approval Date	Mar 19, 2024
Pathway	NDA
Type	New Molecular Entity
Formulation	Tablets
Therapeutic Class	Antihypertensive; Endothelin Receptor Antagonist (ERA)
Expected Market Launch	Availability is anticipated in the 2nd half of 2024.

Approved Indications

TRYVIO™ is an endothelin receptor antagonist indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Mechanism of Action (MoA)

Aprocitentan is an ERA that inhibits the binding of endothelin (ET)-1 to ETA and ETB receptors.

ET-1, via its receptors (ETA and ETB), mediates a variety of deleterious effects such as vasoconstriction, fibrosis, cell proliferation, and inflammation. In hypertension, ET-1 can cause endothelial dysfunction, vascular hypertrophy and remodeling, sympathetic activation, and increased aldosterone synthesis.

Dosing & Administration

The recommended dosage of TRYVIO™ is 12.5 mg orally once daily, with or without food.

Place in Therapy

- TRYVIO™ is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. This therapy targets those whose blood pressure remains uncontrolled with existing treatments, and the clinical trial leading to TRYVIO™'s approval included patients who were on at least three antihypertensive medications.
- The clinical trial was conducted in a "high-risk" population. In addition to the three antihypertensive medications, more than 60% of patients were treated with at least four drugs at screening, more than 50% had diabetes mellitus, and 20% had a history of heart failure.
- TRYVIO™ is the first oral anti-hypertensive therapy which works via a new therapeutic pathway to be approved in almost 40 years. Prior to this approval, there have been no other FDA-approved systemic antihypertensive therapies targeting the endothelin (ET) pathway. Overall, this is a novel therapeutic option that may be a good option in treating resistant hypertension in high-risk patients.
- The main competitor for TRYVIO™ for this indication is expected to be AstraZeneca's baxdrostat. Baxdrostat is a selective aldosterone synthase inhibitor, and is being evaluated in a Phase III BaxHTN trial (NCT06034743). The study is expected to enroll up to 720 participants with resistant hypertension taking two or more hypertensives to control their blood pressure.

Place in Therapy Continued

- Another drug in development for treating resistant hypertension is Novartis' XXB750, a natriuretic peptide receptor 1 (NPR1) agonist. The drug is being evaluated in a Phase II trial (NCT06034743). The study is expected to enroll up to 170 participants and will be completed in September 2024.

Expected Cost

Available only through the REMS program.

Product Discontinuation

Not available